Agapitos joined Antibody Analytics in 2018 from a biotechnology company where, as Head of Product Development, he led discovery and development of cellular therapies for cancer treatment. As an author of more than 10 publications within the field of DC-T cell interactions and autoimmunity and was integral in securing patents within CAR-T therapeutics. Prior to this, he completed his PhD at University of Glasgow focusing on Th17 biology in rheumatoid Arthritis. He continued his scientific career in Glasgow University from 2010 to 2015 investigating DC-T cell interactions.
Within his current role at Antibody Analytics, Agapitos is responsible for establishing new methods and capabilities with our newly established Translational Immunology business unit. He works with customers and internal operations to keep Antibody Analytics are the fore of method development for immuno-oncology, cell therapy and autoimmunity divisions of the biopharmaceutical industry.